CN106456654A - 环磷酰胺液体浓缩制剂 - Google Patents

环磷酰胺液体浓缩制剂 Download PDF

Info

Publication number
CN106456654A
CN106456654A CN201580023235.5A CN201580023235A CN106456654A CN 106456654 A CN106456654 A CN 106456654A CN 201580023235 A CN201580023235 A CN 201580023235A CN 106456654 A CN106456654 A CN 106456654A
Authority
CN
China
Prior art keywords
cyclophosphamide
containing composition
solution
ethanol
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580023235.5A
Other languages
English (en)
Chinese (zh)
Inventor
N·R·帕利普
P·C·巴克斯顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oro Medical Pharmaceutical Co Ltd
Original Assignee
Oro Medical Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54366856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN106456654(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oro Medical Pharmaceutical Co Ltd filed Critical Oro Medical Pharmaceutical Co Ltd
Publication of CN106456654A publication Critical patent/CN106456654A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201580023235.5A 2014-05-09 2015-05-01 环磷酰胺液体浓缩制剂 Pending CN106456654A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461991247P 2014-05-09 2014-05-09
US61/991,247 2014-05-09
PCT/US2015/028862 WO2015171460A2 (en) 2014-05-09 2015-05-01 Formulations of cyclophosphamide liquid concentrate

Publications (1)

Publication Number Publication Date
CN106456654A true CN106456654A (zh) 2017-02-22

Family

ID=54366856

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580023235.5A Pending CN106456654A (zh) 2014-05-09 2015-05-01 环磷酰胺液体浓缩制剂

Country Status (10)

Country Link
US (3) US9662342B2 (enExample)
EP (1) EP3139929A4 (enExample)
JP (1) JP6516831B2 (enExample)
KR (1) KR20170008252A (enExample)
CN (1) CN106456654A (enExample)
AU (1) AU2015256331B2 (enExample)
BR (1) BR112016026140A2 (enExample)
CA (1) CA2948148C (enExample)
RU (1) RU2016147362A (enExample)
WO (1) WO2015171460A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016005962A2 (en) * 2014-07-11 2016-01-14 Dr. Reddy’S Laboratories Limited Stable liquid formulations of cyclophosphamide and processes
US10993952B2 (en) * 2015-02-16 2021-05-04 Leiutis Pharmaceuticals Pvt. Ltd. Stable ready to use cyclophosphamide liquid formulations
WO2020025069A1 (zh) 2018-08-03 2020-02-06 上海宣泰医药科技有限公司 一种水化环磷酰胺冻干组合物的方法及其产品
WO2020178725A1 (en) * 2019-03-04 2020-09-10 Alembic Pharmaceuticals Limited Stable liquid composition of cyclophosphamide
US12433905B2 (en) 2019-07-10 2025-10-07 Intas Pharmaceuticals Ltd. Stable oral composition of cyclophosphamide
WO2021009595A1 (en) * 2019-07-15 2021-01-21 Hetero Healthcare Limited Cyclophosphamide injectable composition and methods for producing same
US20230310468A1 (en) 2020-08-17 2023-10-05 Sandoz Ag Parenteral pharmaceutical composition comprising cyclophosphamide and a mixture of liquids
WO2023059885A1 (en) 2021-10-08 2023-04-13 Slayback Pharma Llc, Stable pharmaceutical compositions of cyclophosphamide
US11642358B1 (en) 2022-02-14 2023-05-09 Extrovis Ag Stable pharmaceutical formulation
WO2024112860A1 (en) * 2022-11-22 2024-05-30 Navinta, Llc Novel solution formulation of cyclophosphamide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952575A (en) * 1986-07-11 1990-08-28 Asta Pharma Aktiengesellschaft Solutions of oxaphosphorins having improved stability and process for the preparation thereof
CN1923280A (zh) * 2005-08-30 2007-03-07 孔庆忠 一种含双氯乙胺类药物的抗癌缓释注射剂
US20140005148A1 (en) * 2012-06-29 2014-01-02 Coldstream Laboratories Inc. Stable liquid formulations of nitrogen mustards

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL99688C (enExample) 1956-12-20
US4879286A (en) 1987-01-28 1989-11-07 Lyphomed, Inc. Cyclophosphamide
US5036060A (en) * 1988-07-25 1991-07-30 Fujisawa Usa, Inc. Cyclophosphamide
CA2039742A1 (en) * 1990-04-23 1991-10-24 Andrew B. Dennis Tablet composition and method for problem pharmaceutical materials
ES2277397T3 (es) * 1997-10-13 2007-07-01 Stada Arzneimittel Ag Formas liquidas de administracion de productos farmaceuticos que contienen oxazafosforina.
US6811788B2 (en) * 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
AUPQ849900A0 (en) * 2000-06-30 2000-07-27 Dbl Australia Pty Ltd. Injectable composition
AU2005295541B2 (en) * 2004-10-15 2011-02-17 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
JP5318403B2 (ja) * 2007-11-30 2013-10-16 株式会社Ｓｏｋｕｄｏ 基板処理装置
US8278220B2 (en) * 2008-08-08 2012-10-02 Fei Company Method to direct pattern metals on a substrate
JP2012510468A (ja) * 2008-11-28 2012-05-10 アボット・ラボラトリーズ 安定な抗体組成物およびこれを安定させるための方法
JP2012530704A (ja) * 2009-06-18 2012-12-06 アボット・ラボラトリーズ 安定なナノ粒子状薬物懸濁液
WO2014068585A1 (en) * 2012-10-29 2014-05-08 Leiutis Pharmaceuticals Pvt. Ltd. Novel lyophilized compositions of cyclophosphamide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952575A (en) * 1986-07-11 1990-08-28 Asta Pharma Aktiengesellschaft Solutions of oxaphosphorins having improved stability and process for the preparation thereof
CN1923280A (zh) * 2005-08-30 2007-03-07 孔庆忠 一种含双氯乙胺类药物的抗癌缓释注射剂
US20140005148A1 (en) * 2012-06-29 2014-01-02 Coldstream Laboratories Inc. Stable liquid formulations of nitrogen mustards

Also Published As

Publication number Publication date
JP2017514924A (ja) 2017-06-08
EP3139929A2 (en) 2017-03-15
US9662342B2 (en) 2017-05-30
RU2016147362A3 (enExample) 2018-10-01
CA2948148A1 (en) 2015-11-12
WO2015171460A3 (en) 2016-04-21
WO2015171460A2 (en) 2015-11-12
EP3139929A4 (en) 2018-01-03
AU2015256331A1 (en) 2016-11-17
US20150320774A1 (en) 2015-11-12
BR112016026140A2 (pt) 2018-08-07
JP6516831B2 (ja) 2019-05-22
CA2948148C (en) 2022-12-06
AU2015256331B2 (en) 2020-03-12
US20170232015A1 (en) 2017-08-17
KR20170008252A (ko) 2017-01-23
RU2016147362A (ru) 2018-06-13
US20150320775A1 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
CN106456654A (zh) 环磷酰胺液体浓缩制剂
JP2018109005A (ja) ベンダムスチン製剤
TWI498128B (zh) 經安定化培美曲塞調配劑
JP2008543789A (ja) ドセタキセルの液体薬学的処方物
RS55491B1 (sr) Formulacije bendamustina
JP6832281B2 (ja) バンコマイシンの水溶液製剤
BR112015028124B1 (pt) Formulação estabilizada de pemetrexed
US20220047509A1 (en) Stabilized liquid formulation of levothyroxine
US20200188478A1 (en) Pre-mixed, ready to use vancomycin compositions
CA2617920C (en) Argatroban formulation comprising an acid as solubilizer
CN108601730B (zh) 万古霉素的制剂
ES2414557B1 (es) Composición acuosa de paracetamol para inyección
JP2019502751A5 (enExample)
TW201412317A (zh) 神經肌肉阻斷劑之穩定化含水組合物
HK1233162A1 (en) Formulations of cyclophosphamide liquid concentrate
EP3220954A2 (en) Process for preparation of parenteral formulation of anidulafungin
JP6033931B2 (ja) 有機溶媒無含有ゲムシタビン水溶液組成物
EP3222271A1 (en) Stable pharmaceutical composition comprising pemetrexed or pharmaceutically acceptable salt thereof
JP2015000869A (ja) 有機溶媒無含有ゲムシタビン水溶液組成物
WO2016059238A1 (en) Pemetrexed formulations

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1233162

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20170222

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1233162

Country of ref document: HK